Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
TORL BioTherapeutics Secures $158 Million for Novel ADC Oncology Pipeline
Details : The financing will continue clinical development of TORL-1-23, a potentially best-in-class ADC for Claudin 6 positive tumors, through Phase 1 and pivotal Phase 2 trials.
Product Name : TORL-1-23
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
October 04, 2024
Details : The net funding will used to advance TORL-1-23, a first-in-class, clinical-stage ADC targeting Claudin 6, TORL-2-307, a clinical-stage ADC targeting Claudin 18.2 and other novel clinical and preclinical stage programs.
Product Name : TORL-1-23
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
April 13, 2023
Reset All
